ATE253565T1 - Inhibitoren der cholesterolesterase - Google Patents

Inhibitoren der cholesterolesterase

Info

Publication number
ATE253565T1
ATE253565T1 AT98918098T AT98918098T ATE253565T1 AT E253565 T1 ATE253565 T1 AT E253565T1 AT 98918098 T AT98918098 T AT 98918098T AT 98918098 T AT98918098 T AT 98918098T AT E253565 T1 ATE253565 T1 AT E253565T1
Authority
AT
Austria
Prior art keywords
inhibitors
cholesterolesterase
present
cholesterol
cholesterol esterase
Prior art date
Application number
AT98918098T
Other languages
English (en)
Inventor
Lorraine Deck
Jagt David L Vander
Original Assignee
Univ New Mexico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New Mexico filed Critical Univ New Mexico
Application granted granted Critical
Publication of ATE253565T1 publication Critical patent/ATE253565T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
AT98918098T 1997-04-16 1998-04-15 Inhibitoren der cholesterolesterase ATE253565T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4198897P 1997-04-16 1997-04-16
PCT/US1998/007263 WO1998046585A1 (en) 1997-04-16 1998-04-15 Inhibitors of cholesterol esterase

Publications (1)

Publication Number Publication Date
ATE253565T1 true ATE253565T1 (de) 2003-11-15

Family

ID=21919442

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03006153T ATE270284T1 (de) 1997-04-16 1998-04-15 Cholesterin esterase inhibitoren
AT98918098T ATE253565T1 (de) 1997-04-16 1998-04-15 Inhibitoren der cholesterolesterase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03006153T ATE270284T1 (de) 1997-04-16 1998-04-15 Cholesterin esterase inhibitoren

Country Status (7)

Country Link
US (3) US5942631A (de)
EP (1) EP0975617B1 (de)
JP (1) JP2002512611A (de)
AT (2) ATE270284T1 (de)
CA (1) CA2284525A1 (de)
DE (2) DE69824901D1 (de)
WO (1) WO1998046585A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EP2234493A4 (de) * 2007-12-21 2011-05-25 Univ Cincinnati Therapeutische verwendung von carboxylesterlipasehemmern
US9061796B2 (en) * 2009-04-23 2015-06-23 H.J. Heinz Company Multi-function condiment container
US20150133551A1 (en) 2012-05-03 2015-05-14 Beth Israel Deaconess Medical Center, Inc. Lipids That Increase Insulin Sensitivity And Methods Of Using The Same
EP2972399B1 (de) 2013-03-15 2020-09-02 Beth Israel Deaconess Medical Center, Inc. Lipide zur erhöhung der insulinempfindlichkeit und verfahren zur verwendung davon

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3056802A (en) * 1960-10-04 1962-10-02 Union Carbide Corp Alpha-halo lactones
US3227736A (en) * 1962-10-31 1966-01-04 Olin Mathieson Production of alpha-fluorocarboxylic acids and esters
US3346594A (en) * 1965-08-25 1967-10-10 Gen Aniline & Film Corp Haloalkyl and polyhaloalkyl lactones
US4338122A (en) * 1979-09-26 1982-07-06 Union Carbide Corporation Biocidal 2-aryl-1,3-cyclopentanedione compounds and alkali metal and ammonium salts thereof
GB2168696B (en) * 1984-12-21 1989-01-11 Boehringer Biochemia Srl Fluoro coumarins as antilymphoedema agents
US5025017A (en) * 1989-09-28 1991-06-18 E. R. Squibb & Sons, Inc. Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates
US5059696A (en) * 1990-03-15 1991-10-22 Merck & Co., Inc. Processes and intermediates for the preparation of 5-oxygenated hmg-coa reductase inhibitors
GB9100174D0 (en) * 1991-01-04 1991-02-20 British Bio Technology Compounds
EP0621892B1 (de) * 1992-11-18 1998-07-08 Firmenich Sa Verwendung von Furanonen wie Duftstoffe
FR2741620B1 (fr) * 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline

Also Published As

Publication number Publication date
ATE270284T1 (de) 2004-07-15
DE69824901D1 (de) 2004-08-05
EP0975617B1 (de) 2003-11-05
WO1998046585A1 (en) 1998-10-22
JP2002512611A (ja) 2002-04-23
CA2284525A1 (en) 1998-10-22
DE69819482D1 (de) 2003-12-11
DE69819482T2 (de) 2004-08-26
US6034255A (en) 2000-03-07
US6114545A (en) 2000-09-05
EP0975617A1 (de) 2000-02-02
EP0975617A4 (de) 2000-09-13
US5942631A (en) 1999-08-24

Similar Documents

Publication Publication Date Title
IS4695A (is) (Metýlsúlfónýl)fenýl-2-(5H)-fúranón sem sýklóoxýgenasa-2 tálmar
ID18143A (id) Penghambat metaloprotease amina siklik tersubstitusi
BG106340A (en) Substituted oxoazaheterocyclyl compounds
DK0966465T3 (da) Inhibitorer af IMPDH-enzymer
YU35802A (sh) Polimorfni oblik atorvastatin kalcijuma
BG104780A (en) Inhibitors of phospholipase enzymes
EA200300155A1 (ru) Терапевтическая комбинация ингибитора сетр и аторвастатина
EP1126849A4 (de) Heterozyklische kalium-kanal inhibitoren
ATE277929T1 (de) Immunsuppressive wirkungen von pteridinderivaten
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
EA200100958A1 (ru) Производные 4,5-диарил-3(2h)-фуранона как ингибиторы циклооксигеназы-2
BR9508308A (pt) Derivados de benzoíla e sintese dos mesmos
MXPA01006469A (es) Combinaciones de inhibidores de proteina de transferencia de ester colesterilico y derivados de acido fibrico para indicaciones cardiovasculares.
SE9901077D0 (sv) Novel use
DK1001761T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsunderskudslidelser
SE9801494D0 (sv) Novel use
BR0014990A (pt) Derivados de tetrahidrotiopirano ranftalazinona como inibidores de pde4
DK0656001T3 (da) Nye 2-substituerede indan-2-mercaptoacetylamid-tricycliske derivater til anvendelse som enkefalinasehæmmere
ATE253565T1 (de) Inhibitoren der cholesterolesterase
DK0996435T3 (da) Aminosyrederivater anvendelige til behandling af slagtilfælde
EA200100930A1 (ru) Способ лечения хозл
NO983511D0 (no) Difenylstilbener som pro-legemidler for COX-2-inhibitorer
DK1165491T3 (da) LTA4-hydrolase-inhibitorer
NO912985L (no) Forbedret system for transdermal applikasjon av farmasoeytisk aktive forbindelser ved regulert ph.
DE60025705D1 (de) Antikonvulsive derivate zur behandlung von essentiellem tremor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties